PARP inhibitors selectively kill tumor cells with defective homologous recombination function caused by BRCA gene mutations, but have no effect on cells with normal BRCA genes.[20] The efficacy of PARP inhibitors has been demonstrated in patients with advanced ovarian cancer and BRCA1/2 mutations. Here, PARP1 is linked to neoplasm.